US Patent

US8283369 — Compounds and compositions and methods of use

Method of Use · Assigned to Ardea Biociences Inc · Expires 2028-11-26 · 3y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects compounds and methods of using them to modulate blood uric acid levels and treat or prevent disorders related to uric acid.

USPTO Abstract

Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.

Drugs covered by this patent

Aloprim (ALLOPURINOL) · Casper Pharma Llc
Zurampic (LESINURAD) · Ironwood Pharms Inc

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2104`	—	Aloprim
`U-2104`	—	Aloprim
`U-1804`	—	Zurampic

Patent Metadata

Patent number: US8283369
Jurisdiction: US
Classification: Method of Use
Expires: 2028-11-26
Drug substance claim: No
Drug product claim: No
Assignee: Ardea Biociences Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.